Drugs / ibuzatrelvir
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07552779 | Apr → Jun 2026 overdue | COVID-19, pneumonia | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07235137 | Oct → Nov 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06693518 | Nov 2024 → Jan 2025 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06646042 | Oct 2024 → Jan 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06586216 | Sep 2024 → Feb 2025 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06122194 | Nov 2023 → Jan 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05884554 | Jun 2023 → Jun 2024 | COVID-19 | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05822440 | Apr → Jul 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05580003 | Oct 2022 → Sep 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05799495 | May → Sep 2023 | COVID-19 | Pfizer | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07013474 | Jul 2025 → Sep 2027 expected | COVID-19 | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06679140 | Dec 2024 → Oct 2027 expected | COVID-19 | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-13 | Pfizer | Results Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 pfizer.com ↗
Ibuzatrelvir Potently Reduced Viral RNA Levels Despite the High Rate of Anti-S Seropositivity: a Post Hoc Analysis of Serology in the Phase 2b Study in Adults Without Risk Factors for Severe COVID-19 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-13 | Pfizer | Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 pfizer.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ibuzatrelvir | “Ibuzatrelvir is an orally bioavailable SARS-CoV-2 Mpro inhibitor with demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions.” PMID 39486089 ↗ Mar 20256“Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg” NCT06693518 ↗ |
| Known as | PF-07817883 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799495 ↗ |
| Action | Inhibit | “SARS-CoV-2 Mpro inhibitor” PMID 41796210 ↗ Mar 2026 |
| Modality | Small molecule | — CHEMBL5591580 ↗ |
| Route | Oral | “Participants will take PF-07817883 by mouth up to 2 times a day.” NCT05580003 ↗ |